| 0.4562 -0.022 (-4.6%) | 03-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.04  |
1-year : | 1.37 |
| Resists | First : | 0.89 |
Second : | 1.17 |
| Pivot price | 0.63 |
|||
| Supports | First : | 0.44 |
Second : | 0.36 |
| MAs | MA(5) : | 0.54 |
MA(20) : | 0.69 |
| MA(100) : | 1.57 |
MA(250) : | 20.51 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 4.7 |
D(3) : | 5.6 |
| RSI | RSI(14): 25.8 |
|||
| 52-week | High : | 168 | Low : | 0.44 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CDT ] has closed below the lower bollinger band by 8.8%. Bollinger Bands are 68.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.51 - 0.51 | 0.51 - 0.52 |
| Low: | 0.44 - 0.44 | 0.44 - 0.44 |
| Close: | 0.45 - 0.46 | 0.46 - 0.46 |
CDT Equity, Inc. engages in facilitating the development and commercialization of clinical assets. The company was founded by David Joszef Tapolczay and Freda C. Lewis-Hall in October 2021 is headquartered in Naples, FL.
Thu, 12 Mar 2026
CDT Equity to map asset portfolio against rare disease database - Investing.com
Thu, 12 Mar 2026
CDT Notes Sarborg Expansion into Rare Disease Signature Intelligence - The Chronicle-Journal
Thu, 12 Mar 2026
CDT Notes Sarborg Expansion into Rare Disease Signature Intelligence - Bitget
Wed, 11 Mar 2026
CDT Stock Price, Quote & Chart | CDT EQUITY INC (NASDAQ:CDT) - ChartMill
Tue, 10 Mar 2026
CDT Equity Expands Financing Through New Convertible Note - The Globe and Mail
Mon, 09 Mar 2026
CDT Equity (CDT) lowers ELOC floor and issues $555,556 secured convertible note - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 39.8 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 74 (K) |
| Shares Short P.Month | 68 (K) |
| EPS | -179.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -207 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|